Copy number alteration burden predicts prostate cancer relapse

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11139-11144

  Hieronymus, Haley ^a   Schultz, Nikolaus ^a   Gopalan, Anuradha ^a   Carver, Brett S ^a   Chang, Matthew T ^a   Xiao, Yonghong ^a   Heguy, Adriana ^a,b   Huberman, Kety ^a   Bernstein, Melanie ^a   Assel, Melissa ^b   Murali, Rajmohan ^a   Vickers, Andrew ^b   Scardino, Peter T ^a   Sander, Chris ^a   Reuter, Victor ^a   Taylor, Barry S ^b,c,d   Sawyers, Charles L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; Oncology; Prognosis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; COPY NUMBER ALTERATION; FOLLOW UP; GENE DOSAGE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER;

GENOMICS; ONCOLOGY; PROGNOSIS;

BIOPSY, NEEDLE; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904990669     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411446111     Document Type: Article

References (30)

1. Draisma G, et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 101(6):374-383.
2. Wilt TJ, et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203-213.
3. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM (2012) Beyond PSA: The next generation of prostate cancer biomarkers. Sci Trans Med 4(127):127rv123.
4. Lughezzani G, et al. (2010) Predictive and prognostic models in radical prostatectomy candidates: A critical analysis of the literature. Eur Urol 58(5):687-700.
5. Wong LM, et al. (2012) International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Br J Cancer 107(9):1467-1473.
6. Cary KC, et al. (2013) Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: The value of the pattern of surveillance biopsies. Eur Urol, 10.1016/j.eururo.2013.08.060.
7. Irshad S, et al. (2013) A molecular signature predictive of indolent prostate cancer. Sci Trans Med 5(202):202ra122.
8. Erho N, et al. (2013) Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 8(6):e66855.
9. Cuzick J, et al.; Transatlantic Prostate Group (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106(6):1095-1099.
10. Leary RJ, et al. (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Trans Med 4(162):162ra154.
11. Cheng I, et al. (2012) Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 51(1):66-76.
12. Sboner A, et al. (2010) Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 3:8.
13. Yu YP, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22(14):2790-2799. (Pubitemid 41079896)
14. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
15. Wang ZA, et al. (2013) Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 15(3):274-283.
16. Lunardi A, et al. (2013) A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 45(7):747-755.
17. Ding Z, et al. (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470(7333):269-273.
18. Ding Z, et al. (2012) Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148(5):896-907.
19. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52):21276-21281.
20. Qi J, et al. (2013) The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 23(3):332-346.
21. Stephenson AJ, et al. (2005) Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J ClinOncol 23(28):7005-7012.
22. Barbieri CE, et al. (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685-689.
23. Taylor BS, et al. (2008) Functional copy-number alterations in cancer. PLoS ONE 3(9):e3179.
24. Liu W, et al. (2013) Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 119(13):2405-2412.
25. Daskivich TJ, et al. (2011) Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117(10):2058-2066.
26. Bill-Axelson A, et al.; SPCG-4 Investigators (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708-1717.
27. Erho N, Buerki C, Triche TJ, Davicioni E, Vergara IA (2012) Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012:541353.
28. Antonarakis ES, et al. (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up. BJU Int 109(1):32-39.
29. Frampton GM, et al. (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31(11):1023-1031.
30. Schweiger MR, et al. (2009) Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS ONE 4(5):e5548.